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ted inSingle high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC) support improves
complete response and overall survival (OS) in untreated aggressive non-Hodgkin’s lymphoma (NHL). How-
ever, patients with a high age-adjusted international prognostic index (aa-IPI equal to 3) still have poor clinical
outcome despite high dose intensity regimen. To improve complete response in this subgroup, the French
Groupe Ouest-Est des Leucemies et Autres Maladies du Sang (GOELAMS) conducted a pilot phase II trial
(073) evaluating tandem HDTwith PBSC support in a series of 45 patients with aa-IPI equal to 3 untreated
aggressive non-Hodgkin’s lymphoma. After induction with an anthracyclin-containing regimen, responders
underwent tandem HDT conditioned by high-dose mitoxantrone plus cytarabine for the first HDT and
total-body irradiation (TBI), carmustine, etoposide, and cyclophosphamide for the second HDT. Thirty-
one patients out of 41 evaluable patients completed the program. There were 4 toxic deaths. The complete
response ratewas 49%.With amedian follow-up of 114months for surviving patients, theOSwas 51%, and 19
out of the 22 patients (86%) who reached a complete response are alive and relapse-free. Recent prospective
evaluation of quality of life and comorbidities of surviving patients does not reveal long-term toxicities of the
procedure. In the era of monoclonal antibodies and response-adapted therapy, the role of tandem HDT still
need to be determined.
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In 1993, the age-adjusted International Prognostic
Index (aa-IPI) was set up to predict survival of patients
under 60 years of age with aggressive non-Hodgkin’s
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mance status), 4 prognostic groups were defined: low,
low intermediate, high intermediate, and high. In the lat-
ter group, after CHOP-like regimens, the complete re-
sponse (CR) and 5-year overall survival (OS) rates wereClinicaltrials.gov identifier: NCT00869284
Financial disclosure: See Acknowledgments on page 939.
*H.M. and E.D. contributed equally to the work.
Correspondence and reprint requests: Emmanuel Gyan, Service
d’hematologie et therapie cellulaire,CHUdeTours,Ho^pital Bre-
tonneau, 2, boulevard Tonnelle, 37000 Tours, France (e-mail:
emmanuel.gyan@univ-tours.fr) and No€el Milpied, Service des
maladies du sang, Ho^pital Haut-Leve^que, 1 avenue Magellan,
33600 Pessac, France (e-mail: noel.milpied@chu-bordeaux.fr).
Received January 22, 2010; accepted November 11, 2010




936 Biol Blood Marrow Transplant 17:935-940, 2011H. Monjanel et al.46% and 32%, respectively. Improved CR and OS have
beendescribedwith single high-dose therapy (HDT) fol-
lowed by autologous peripheral blood stem cell (PBSC)
support in first-line treatment of aggressive NHL, but
high-risk patients still have a poor prognosis [2,3]. In an
attempt to improve the outcome of these patients,
before the era of monoclonal antibodies, the French
Groupe Ouest-Est des Leucemies et Autres Maladies
du Sang (GOELAMS) conducted the 073 study to
evaluate upfront tandem HDT with PBSC support in
aggressive NHL patients with high aa-IPI.DESIGN AND METHODS
Inclusion Criteria
This phase II multicenter study enrolled patients
aged from 15 to 60 years with previously untreated his-
tologically proven aggressive NHL: F, G, H according
to the Working Formulation [4] (WHO classification
was not published when the study was designed),
a high aa-IPI (equal to 3), proper underlying organ
function, and absence of HIV infection. Patients with
transformed low-grade, lymphoblastic, mantle-cell,
or Burkitt’s lymphoma were excluded. The trial was
approved by the Ethics Committee of the Region
Pays de la Loire, France, on 01/09/1994. All patients
provided written informed consent.Treatment
Two courses of the CEEP regimen were planned
with cyclophosphamide 1200 mg/m2, epirubicin
100 mg/m2, vindesine 3 mg/m2 intravenously on day
1 and prednisone 80 mg/m2 orally or intravenously
from days 1 to 5, at 2-week intervals. Granulocyte
colony-stimulating growth factor (filgrastim, Amgen,
Neuilly-sur-Seine, France) was administrated at the
dose of 5 mg/kg/day from day 6 of each course of
CEEP, until apheresis procedures were completed.
Intrathecal injections of 15 mg methotrexate and
20 mg methylprednisolone were routinely given on
the second day of each CEEP course.
ThefirstHDT(HDT1)wasplannedonday36.The
conditioning regimen was mitoxantrone 45 mg/m2
intravenously on day 1 and cytarabine 1000 mg/m2 by
a 3-hour infusion every 12 hours from days 1 to 4.
Patients were eligible for the second HDT (HDT2) if
they reached at least a partial response (PR) after
HDT1. The conditioning regimen of HDT 2 started
from day 30 to day 45 after the first stem cell infusion,
and consisted of 1200 cGy total-body irradiation
(TBI) in 6 twice-daily 200 cGy fractionated doses with
a 800 cGy pulmonary shielding, followed by CBV: car-
mustine 300 mg/m2 intravenously on day 4, and etopo-
side 200 mg/m2 and cyclophosphamide 1500 mg/m2
intravenously from days 5 to 8. For each HDT, at least2  106/kg CD341 unpurged PBSC were infused the
day following the last chemotherapy, and 5 mg/kg/day
filgrastim was started on the same day. Because 3 pa-
tients out of 16 patients who had received HDT2
experienced lethal toxicity, the intensity of the TBI-
containing regimenwas reduced toTBI (same schedule)
1 cyclophosphamide (60 mg/kg for 2 days).
Staging and Assessments
Patients were staged at diagnosis by clinical exam-
ination, CT scan, and bone marrow (BM) biopsy.
Diagnostic slides were reviewed centrally by 1 pathol-
ogist (A.M.). The evaluation responses by CT scan
were planned after HDT1 and HDT2.
Response Assessments
The standardization of response evaluations for
lymphoma was not published at the time of study de-
sign [5]. CR was defined by the disappearance of all
documented disease. Additionally, patients with persis-
tent CT abnormalities but reduction of at least 75% in
the largest diameter of all measurable lesions without
the persistence of BM involvement were deemed to
be in CR. PR was defined by a reduction of at least
50% in the largest diameter of everymeasurable lesion,
even if BM involvement persisted. Treatment was con-
sidered to have failed if patients experienced disease
progression before the end of the treatment program.
Follow-Up
Patients were monitored by physical examination
every 3 months for the first 2 years, every 6 months
for the next 2 years, and annually thereafter. CT scans
were performed every 6 months during the first 2 years
and then at the discretion of the treating physician. As
a part of this long-term evaluation of the procedure,
survivors were assessed for health-related quality of
life (HRQoL) and comorbidities with the EORTC
QLQ-30, version 2 [6] and the Self-Administered
Comorbidity Questionnaire (SCQ) [7], respectively.
Statistical Analysis
The primary endpoint was the CR rate. With a hy-
pothesis of improving the CR rate from 46% [1] to
60%, more than 40 patients had to be included to en-
sure that the lower limit of the 95% confidence interval
(CI) around 60% will be .40%. Thus, this pilot study
was planned to include 45 patients with an interim anal-
ysis after the first 20 inclusions. Secondary endpoints
were the overall response (OR), OS, progression-free
survival (PFS) rates, and toxicity. OR was defined as the
addition ofCR and PR;OSwasmeasured from the time
of inclusion to death from any cause or the date of last
contact; PFS was measured from the time of inclusion
to relapse or death in remission. OS and PFS rates
were calculated according to theKaplan-Meiermethod.
Biol Blood Marrow Transplant 17:935-940, 2011 937Tandem HDT for High-Risk Aggressive NHLThe log-rank test was used to compare the survival
curves between groups. Univariate analysis and multi-
variate analysis were performed with the use of the
Cox model. Variables with a P value lower than 0.25
in the univariate analysis were retained for the multivar-
iate analysis. The Cox regression gave hazard ratio
(HR). The type I error was set to 5%. Statistical analysis
was performed with the R software version 2.7.2. All
parameters were evaluated on an intent-to-treat basis.RESULTS
We report on the results of tandem HDT in a spe-
cifically adverse prognostic population of aggressive
NHL patients.Description of Patients and Treatment
Outcome
Between October 1994 and July 1999, 45 patients
were included in 10 GOELAMS centers. Four patients
were excluded from the analysis because of inclusion
criteria violations (aa-IPI\3 for all). Characteristics of
the 41 patients at inclusion are summarized in Table 1.
A total of 31 patients (76%) completed the whole proce-
dure. The 10 others experienced early progression (n5
5), toxic death (n5 1), protocol violations (n5 3), and
hepatitis B reactivation after HDT1 (n 5 1). A total of
4 toxic deaths occurred during treatment: bacterial
septicemia after the first CEEP (n 5 1), and after






Diffuse mixed small and large cell (F) 1 (2)
Diffuse large cell (G) 31 (76)
Large cell immunoblastic (H) 3 (7)
Ki-1 positive anaplastic 1 (2)
Peripheral T cell 2 (6)
Other 3 (7)








Nodal involvement $4 16 (39)
Extranodal involvement $2 23 (56)
Bulky disease ($10 cm)
Abdominal 7 (17)
Thoracic 2 (6)
Serous effusion 18 (44)
Marrow involvement 15 (37)
N indicates number of patients.and hemorrhagic shock). HDT2 conditioning was sub-
sequently reduced, resulting in the absence of additional
lethal toxicity (Figure1).All patientsmobilized correctly
with amedian of 2 aphereses (required PBSCdose/kg5
4  106 CD341). Hematologic toxicity was acceptable,
with a median duration of neutropenia (neutrophil
count \0.5  109/L) of 9 and 11 days following
HDT1 and HDT2, respectively.Response and Survival Analysis
Eighteen patients (40%) experienced a CR after
HDT1 and 22 patients (49%) after HDT2. OR was
achieved for 32 patients (71%) after HDT1 and for 26
patients (58%) after HDT2. With a median follow-up
time of 114 months (range: 23-159), 10-year OS and
PFS are estimated by 51% (95% confidence interval
[CI] 38%-69%) and 53% (95% CI 38%-73%), respec-
tively (Figure 2).
All patients who survived after 10 months, except
1, were relapse-free to date. The patient who relapsed
with a nonaggressive histology (follicular) was success-
fully treated using rituximab alone. The occurrence of
a plateau after 10 months suggests that a subgroup of
aa-IPI equal to 3 patients with aggressive NHL might
be cured by tandem autologous HDT.Figure 1. Flowchart of the patients included in the GOELAMS 073
trial. C indicates cyclophosphamide; CBV, carmustine, etoposide, and
cyclophosphamide; CEEP, cyclophosphamide, epirubicin, vindesine, and
prednisone; HDT, high-dose therapy; N, number of patients; PBSC,
peripheral blood stem cell; TBI, total-body irradiation.
Figure 2. Patient outcomes. (A) OS. (B) PFS.




Median score (95% CI) 86 (53-100)




Median score (95% CI) 85 (33-100)




Median score (95% CI) 74 (8-100)




Median score (95% CI) 79 (33-100)




Median score (95% CI) 74 (17-100)




Median score (95% CI) 32 (0-78)
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Fifteen patients experienced progressive disease or
relapse after completion of the whole procedure.
Among the 9 patients for which relapse site informa-
tion was available, 8 (89%) relapsed at the initial dis-
ease site. One patient, who had a history of brain
disease at enrollment, experienced relapse in the cen-
tral nervous system.Mean score (IQR) 33 (22-44)
n <50 2
% <50 16%
Global quality of life
Median score (95% CI) 68 (0-100)
Mean score (IQR) 71 (67-75)
n <50 1
% <50 8%
IQR, Indicates interquatile range; N, number of patients; CI, confidence
interval.Prognostic Factors
In a univariate analysis, OS was negatively affected
by serous effusion (P5 .042), and a favorable progno-
sis of the G and H histology subtypes (P 5 .014) was
observed. PFS was affected by histology (P 5 .004)
only. On multivariate analysis, G and H histologysubtypes and serous effusion remained statistically
significant (HR: 3.9, 95%CI: 1.17%-12.91% andHR:
2.9, 95% CI: 1.04%-8.68%, respectively) for OS,
G and H histologies (HR: 8.5, 95% CI: 1.83%-
39.47%) for PFS.
Long-Term Toxicity
Three nonfatal secondary malignancies have oc-
curred: 1 adenoid cystic carcinoma treatedby surgery and
2 breast cancer treated with radiochemotherapy or with
surgery. Of note, no myelodysplastic syndrome or sec-
ondary acutemyeloblastic leukemiahadoccurred todate.
Quality of Life and Medical Late Effects
Twenty-three patients were eligible for the long-
term HRQoL questionnaire and SCQ. Of these, 5
were lost to follow-up and 6 either actively or passively
declined participation.
For the EORTCQLQ-30 functioning scales, 82%
of patients scored 50 or above, representing good qual-
ity of life, on the global health status scale, and no pa-
tients scored 50 or below on the physical functioning
scale. Only a small proportion of patients had scores
Table 3. FrequencyandPercentageof SelectedSelf-Reported
Late Effects
Late effects n (%)
Number 8 (67)
Cardiopulmonary impairments 4 (33)
Hypertension 2 (17)
Dyspnea 3 (25)
Neuromotor impairments 3 (25)
Tremor, weakness or balance 3 (25)
Psychiatric disorders 3 (25)
Depressive syndrome 2 (17)
Bipolar affective disorder 1 (8)
Endocrine impairments 2 (17)
Sterility 1 (8)
Diabetes 1 (8)
Neurosensory impairments 2 (17)
Vertigo 1 (8)
Tinnitus or ringing in the ears 1 (8)
Eye impairments 2 (17)
Cataracts 2 (17)
Hematologic impairments 2 (17)
Anemia 2 (17)
Exocrine impairments 1 (8)
Pancreatic insufficiency 1 (8)
Bone impairments 1 (8)
Osteoporosis 1 (8)
Renal impairments 1 (8)
Chronic renal failure 1 (8)
n indicates number of patients.
Biol Blood Marrow Transplant 17:935-940, 2011 939Tandem HDT for High-Risk Aggressive NHLof 50 or below on the role, emotional, cognitive, and
social functioning scales (8% to 16%). For the symp-
tom scales, 16% of patients scored over 50 on the
fatigue scale, which thus represents the most common
symptom (Table 2).
The prevalence of selected medical late effects in
long-term survivors is listed in Table 3. Among pa-
tients who responded to the SCQ questionnaire, the
following conditions were reported: 3 breathing prob-
lems, 5 neuromotor and/or neurosensory impairments,
2 major depressions, 1 bipolar affective disorder, 1
infertility, 2 cataracts, 1 pancreatic insufficiency, 1
osteoporosis, and 1 chronic renal failure.DISCUSSION
Other studies evaluating upfront tandem HDT in
the setting of aa-IPI 1 to 3 aggressive NHL reported
CR rates between 50% and 92% and 3-year OS rates
between 41% and 84% [8-10]. To the best of our
knowledge, this study is the first to evaluate tandem
HDT in the specific setting of untreated high-risk ag-
gressive NHL (aa-IPI equal to 3). With a CR rate of
49% and a 10-year OS estimate of 51%, the 073 trial
compares favorably with other studies.
As in other tandem HDT studies, in this high-risk
population of patients, an intensified induction regi-
men byCEEPwas chosen. The use of this not standard
and generally more intensive treatment might have
positively affected relapse and survival rates. An other
important prognostic factor in this subgroup is the
quality of remission before HDT. Unfortunately, inthis study, the disease status before the first HDT
was not evaluated, and consequently cannot be used
as prognostic factor.
The toxicity of this tandemHDTprocedure partially
impaired the results in terms of OS. In other tandem
HDT studies, improved results were obtained using
non-TBI myeloablative regimens [8-10]. However, our
results are not inferior to those published in frontline
single HDT [11-13] and raise the question of the role
of TBI, as previously discussed in other studies [14,15].
In this study, we examined long-term quality of life
among surviving patients. Scores are similar (mean dif-
ference\10 points) [16] to those of long-term survi-
vors of Hodgkin lymphoma [17,18]. Most survivors
of aggressive NHL enjoyed normal life after tandem
HDT.
Whether a high aa-IPI score was an appropriate
definition of a poor-risk patient population is ques-
tionable, because other prognostic factors have been
identified, such as bulky disease [19], b-2 microglobu-
lin [20], genomic profiling [21,22], and failure to
achieve complete response in the era of positon
emission tomography evaluation [23]. Alternatively
to performing tandem autologous transplantation,
chemotherapy may be intensified. However, the role
of this approach has not yet been demonstrated in
poor-risk aggressive NHL [24].
Additionof rituximab to standard chemotherapy has
shown to improve outcome in older patients with
aggressive NHL. Rituximab, in addition to single
HDT in untreated aggressive NHL, improved CR and
PFS. however with mixed aa-IPI [25,26]. Rituximab-
containing induction chemotherapy followedby a single
transplant is currently being compared to standard
immunochemotherapy as first-line treatment by the
GOELAMS group. The question about the clinical
benefit of adding rituximab to tandem HDT remains
unanswered.
In the absence of randomized trials, the clinical
benefit of tandem HDT still needs to be determined
in the worst prognostic group of patients with aggres-
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